You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Therapy-associated Lymphoid Proliferations

Bagg, Adam MD

Advances in Anatomic Pathology:
doi: 10.1097/PAP.0b013e31821698ef
Review Articles
Abstract

Therapy-related lymphoid proliferations are well described in the setting of iatrogenic immunosuppress ion after transplantation. More recently, however, they have also been observed in patients being treated for a number of other conditions. This brief review will focus on 2 such scenarios, each with quite divergent pathogeneses and consequences. In therapy-related acute lymphoblastic leukemia, the typical setting is prior chemotherapy (typically topoisomerase II inhibitors) for an unrelated neoplasm, in which direct cytotoxic DNA damage is likely to be the primary cause. By contrast, those arising in the setting of autoimmune diseases are more heterogeneous, not always overtly neoplastic and mechanistically complex. This heterogeneity and complexity is based upon, among others, the nature of the underlying disease as well as the variability of different and sometimes sequential or concomitant therapeutic interventions.

Author Information

Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

AB is supported by a grant from the Leukemia and Lymphoma Society of America.

Reprints: Adam Bagg, MD, Department of Pathology & Laboratory Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104-4283 (e-mail: adambagg@mail.med.upenn.edu).

© 2011 Lippincott Williams & Wilkins, Inc.